76-90 of 440
Diagnosing and Staging Non-Small Cell Lung Cancer: Key Updates and Evolving Strategies
Deep Breaths: Updates from CHESTDiagnosing and Staging Non-Small Cell Lung Cancer: Key Updates and Evolving Strategies
Optimizing NSCLC Care: Advances in Lung Biopsy and Biomarker Testing
Deep Breaths: Updates from CHESTOptimizing NSCLC Care: Advances in Lung Biopsy and Biomarker Testing
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Project Oncology®Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Project Oncology®Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Project Oncology®Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Impact of DLL3-Directed Immunotherapy on the Small Cell Lung Cancer Landscape
Project Oncology®Impact of DLL3-Directed Immunotherapy on the Small Cell Lung Cancer Landscape
- advertisement
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®Diagnosing LCNEC of the Lung: Challenges and Strategies
Decoding COPD: Precision Medicine Approaches for Complex Patient Profiles
On the Frontlines of COPDDecoding COPD: Precision Medicine Approaches for Complex Patient Profiles
The Future of Precision Medicine in COPD Care: Biomarkers, AI, and Multimodal Data
On the Frontlines of COPDThe Future of Precision Medicine in COPD Care: Biomarkers, AI, and Multimodal Data
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
On the Frontlines of COPDECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
- advertisement
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Project Oncology®Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Project Oncology®Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Bridging the Gap in COPD Care: A Primary Care and Pulmonary Partnership
On the Frontlines of COPDBridging the Gap in COPD Care: A Primary Care and Pulmonary Partnership
